These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 15002339)

  • 1. Memantine: an antiglutamatergic option for dementia.
    Molinuevo JL; Garcia-Gil V; Villar A
    Am J Alzheimers Dis Other Demen; 2004; 19(1):10-8. PubMed ID: 15002339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Memantine: targeting glutamate excitotoxicity in Alzheimer's disease and other dementias.
    Molinuevo JL; Lladó A; Rami L
    Am J Alzheimers Dis Other Demen; 2005; 20(2):77-85. PubMed ID: 15844753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Memantine].
    Molinuevo JL
    Neurologia; 2003 Jun; 18(5):255-61. PubMed ID: 12768511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism.
    Lipton SA
    Curr Alzheimer Res; 2005 Apr; 2(2):155-65. PubMed ID: 15974913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
    Lipton SA
    J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S61-74. PubMed ID: 15665416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation.
    Lipton SA
    Curr Drug Targets; 2007 May; 8(5):621-32. PubMed ID: 17504105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Glutamate-related excitotoxicity neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer's disease and vascular dementia].
    Tanović A; Alfaro V
    Rev Neurol; 2006 May 16-31; 42(10):607-16. PubMed ID: 16703529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
    Sonkusare SK; Kaul CL; Ramarao P
    Pharmacol Res; 2005 Jan; 51(1):1-17. PubMed ID: 15519530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy of memantine in the treatment of Alzheimer's disease].
    Molinuevo Guix JL; Lladó Plarrumaní A
    Neurologia; 2005 Dec; 20(10):686-91. PubMed ID: 16317590
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Memantine: pharmacological properties and clinical uses.
    Kumar S
    Neurol India; 2004 Sep; 52(3):307-9. PubMed ID: 15472417
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Memantine-sulfur containing antioxidant conjugates as potential prodrugs to improve the treatment of Alzheimer's disease.
    Sozio P; Cerasa LS; Laserra S; Cacciatore I; Cornacchia C; Di Filippo ES; Fulle S; Fontana A; Di Crescenzo A; Grilli M; Marchi M; Di Stefano A
    Eur J Pharm Sci; 2013 May; 49(2):187-98. PubMed ID: 23454012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Classics in Chemical Neuroscience: Memantine.
    Alam S; Lingenfelter KS; Bender AM; Lindsley CW
    ACS Chem Neurosci; 2017 Sep; 8(9):1823-1829. PubMed ID: 28737885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treating the full spectrum of dementia with memantine.
    Winblad B; Jelic V
    Int J Geriatr Psychiatry; 2003 Sep; 18(Suppl 1):S41-6. PubMed ID: 12973749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease.
    Rogawski MA; Wenk GL
    CNS Drug Rev; 2003; 9(3):275-308. PubMed ID: 14530799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Memantine in dementia: a review of the current evidence.
    Herrmann N; Li A; Lanctôt K
    Expert Opin Pharmacother; 2011 Apr; 12(5):787-800. PubMed ID: 21385152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Memantine. Merz.
    Kilpatrick GJ; Tilbrook GS
    Curr Opin Investig Drugs; 2002 May; 3(5):798-806. PubMed ID: 12090556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults.
    Lipton SA
    NeuroRx; 2004 Jan; 1(1):101-10. PubMed ID: 15717010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Memantine hydrochloride in the treatment of dementia subtypes.
    Peng D; Yuan X; Zhu R
    J Clin Neurosci; 2013 Nov; 20(11):1482-5. PubMed ID: 24035650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced Structure-activity Relationships Applied to Mentha spicata L. Subsp. spicata Essential Oil Compounds as AChE and NMDA Ligands, in Comparison with Donepezil, Galantamine and Memantine - New Approach in Brain Disorders Pharmacology.
    Avram S; Mernea M; Bagci E; Hritcu L; Borcan LC; Mihailescu DF
    CNS Neurol Disord Drug Targets; 2017; 16(7):800-811. PubMed ID: 28088901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond.
    Lipton SA
    Nat Rev Drug Discov; 2006 Feb; 5(2):160-70. PubMed ID: 16424917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.